Streetbeat News

Products Services

HOWL

Werewolf Therapeutics, Inc. (HOWL) announced its WTX-124 clinical abstract has been accepted for presentation at the 2024 ASCO Annual Meeting. The update will cover the ongoing Phase 1/1b study of WTX-124 in advanced or metastatic solid tumors. The presentation will detail initial results of the combination dose escalation with pembrolizumab, highlighting Werewolf's progress in developing conditionally activated therapeutics for cancer treatment.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 2:05 pm

CGON

CG Oncology, Inc. (NASDAQ:CGON) announced that the final results of its Phase 2 trial of cretostimogene in combination with pembrolizumab will be presented at the ASCO 2024 Annual Meeting. The trial, CORE-001, focuses on a bladder-sparing therapeutic for patients with bladder cancer. The presentation will detail the trial's findings on the treatment of BCG-Unresponsive, Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 2:04 pm

AUTL

Autolus Therapeutics plc (NASDAQ:AUTL) announced that an abstract from the Phase 2 FELIX study of obe-cel for adult r/r B-ALL has been selected for oral presentation at the 2024 ASCO Annual Meeting. The study focuses on overall survival, event-free survival, and the impact of CAR-T cell persistency and stem cell transplantation. A conference call and webcast to discuss the data will be held on June 1, 2024.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 2:04 pm

CRBU

Caribou Biosciences, Inc. (NASDAQ:CRBU) announced its participation in the 2024 ASCO Annual Meeting with two abstracts on its CRISPR genome-editing CAR-T cell therapies, CB-010 and CB-012, for r/r B-NHL and r/r AML, respectively. CB-010, a first-in-clinic allogeneic CAR-T therapy with a PD-1 knockout, targets B cell non-Hodgkin lymphoma and has received FDA designations including RMAT, Fast Track, and Orphan Drug. CB-012, targeting acute myeloid leukemia, features five genome edits for enhanced antitumor activity. Both presentations aim to showcase initial data and trial designs.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 2:03 pm

TSLA

Tesla Inc (NASDAQ:TSLA) shares surged on Wednesday despite reporting Q1 financial results that missed analyst estimates, with revenue at $21.301 billion versus the expected $22.151 billion, and adjusted earnings of 45 cents per share against the forecast of 51 cents. The stock's rise is attributed to Tesla's accelerated new model launch timeline and CEO Elon Musk's focus on AI, Full Self-Driving, and the announcement of the 'CyberCab' robotaxi. Analysts have mixed reactions, with price target adjustments and an upgrade from BofA Securities from Neutral to Buy.

Portfolio Pulse from Adam Eckert

April 24, 2024 | 1:54 pm

TSLA

Elon Musk, during Tesla's Q1 earnings call, emphasized viewing Tesla (NASDAQ: TSLA) as an AI or robotics company rather than just an auto company, aligning with Cathie Wood's perspective. Despite a sales drop in China, Tesla performed better than competitors in the March 2024 quarter. Musk's comments follow Tesla's revenue report of $21 billion, missing Wall Street's $22.15 billion estimate. He stressed Tesla's focus on autonomy and AI, mentioning talks with a major automaker to license its Full Self-Driving software.

Portfolio Pulse from Rounak Jain

April 24, 2024 | 1:53 pm

MSTR

Recent options market activity indicates a bearish stance on MicroStrategy (NASDAQ:MSTR), with a significant portion of trades showing bearish expectations. Despite this, there's a targeted price range from $980 to $3800. Notable options activity includes both bullish and bearish sentiments with varying strike prices and expirations. MicroStrategy, a provider of enterprise analytics and mobility software, has seen its stock price decrease by -1.56%, with analysts maintaining buy ratings and target prices averaging $1828.33.

Portfolio Pulse from Benzinga Insights

April 24, 2024 | 1:47 pm

VRT

Vertiv Holdings (NYSE:VRT) has seen significant options trading activity, indicating a mixed market sentiment among big-money investors. The trading activity suggests a price target range of $76 to $110 for VRT over the next three months. Notable options trades include a mix of bullish and bearish sentiments, with a total of 11 trades observed. The company, specializing in solutions for data centers, communication networks, and commercial and industrial facilities, has seen its stock price increase by 13.48% to $89.84. Analysts have set an average price target of $95.75 for VRT, with ratings ranging from Overweight to Outperform.

Portfolio Pulse from Benzinga Insights

April 24, 2024 | 1:47 pm

BKR

Baker Hughes forecasts a 20% increase in natural gas demand through 2040, with mid-single digit growth in LNG demand expected until the end of the decade, as discussed in their conference call.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 1:45 pm

MRT

Marti's ride-hailing service has surpassed 788,000 riders and 145,000 registered drivers. The company has updated its June 30, 2024, unique rider target from 850,000 to 900,000, while keeping its registered driver target at 155,000.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 1:42 pm